Safety and Efficacy of C21 in Subjects With COVID-19
Status:
Completed
Trial end date:
2020-10-13
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo-controlled phase 2 trial investigating the safety
and efficacy of C21 in subjects who are hospitalised with COVID-19 infection, but not in need
of mechanical invasive or non-invasive ventilation.
In total, approximately 100 subjects will be enrolled and randomised to receive twice daily
oral administration of either standard of care (SoC) + placebo (N=50) or SoC + C21 (N=50).
Subjects will be treated for 7 days.